Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md., Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax' COVID-19 vaccine, which will be marketed in the European Union under the brand name Nuvaxovid™.

Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization

Novavax may soon get authorisation from several countries and this will take the revenue to record high. NVAX stock is a long term buy.

Novavax Stock Is a Long-Term Investment in an Extended Pandemic

Novavax Inc. NVAX, -1.14% and Serum Institute of India said Wednesday that the Philippine Food and Drug Administration has granted emergency use authorization to Novavax' COVID-19 vaccine with Matrix-M(TM) adjuvant. The vaccine will be made in the Philippines by the SII under the brand name Covovax.

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

GAITHERSBURG, Md. and PUNE, India, Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased acquired Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). Novavax investors have until January 11, 2022 to file a lead plaintiff motion. Investors suffering losses on their Novavax investments are encouraged to contact the Law Offices of Howard G. Sm

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Novavax, Inc. (NVAX) Investors

SAN DIEGO--(BUSINESS WIRE)-- #NVAXstock--The suit alleges defendants issued false statements concerning Novavax business and prospects, resulting in its stock trading at inflated prices.

DEADLINE: Novavax, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NVAX

SAN DIEGO--(BUSINESS WIRE)---- $NVAX #COVID19--Novavax, Inc. (NVAX) Misled Shareholders Regarding Approval of its COVID Vaccine

SHAREHOLDER ALERT: Robbins LLP Informs Investors of Class Action Against Novavax, Inc. (NVAX)

Los Angeles, California--(Newsfile Corp. - November 16, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novavax is the subject of an article published by Politico on October...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novavax, Inc. and Encourages Investors with Losses to Contact the Firm

Amarin Corporation Plc

ON24

NEW YORK, NY / ACCESSWIRE / November 16, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: AMRN ONTF NVAX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

It might be tempting to short a ridiculous micro cap that has no future, but it's actually very dangerous.

Why Shorting a Penny Stock Is a Bad Idea

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period") have until January 11, 2022 to seek appointment as lead plaintiff in Sinnathurai v. Novavax, Inc., No.

ALERT: Novavax, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NVAX

The company reported some good news in an important Asian market.

Why Novavax Beat the Market on Monday

Boston, Massachusetts--(Newsfile Corp. - November 15, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX), a biotechnology company with headquarters in Gaithersburg, Maryland. Novavax purports to be "conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19."About the Securities Class Action FiledOn November 12, 2021, a securities class action complaint was filed...

NVAX Alert: Berman Tabacco Alerts Investors with Losses in Excess of $100,000 of Deadline for Seeking Appointment as Lead Plaintiff in Novavax, Inc. Class Action

Los Angeles, California--(Newsfile Corp. - November 15, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novavax is the subject of an article published by Politico on October...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novavax, Inc. and Encourages Investors with Losses to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - November 15, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Novavax, Inc. (NASDAQ: NVAX) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/nvax.What is this all about?On October 19, 2021, after the market closed, Politico published an article, titled...

LAWSUIT FILED - Novavax Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company in South Korea, today announced the submission of a Biologics License Application (BLA) for Novavax' COVID-19 vaccine to South Korea's Ministry of Food and Drug Safety (MFDS).

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

BioNTech SE

Political messaging around the necessity of covid booster shots is once again following the “optics” script rather than the scientific script. The SARS-CoV-2 virus is a permanent addition to human infectious viruses. It's here to stay.

BioNTech: The Novavax Fork In The Road

NVAX has fallen sharply recently, but the time is ripe to buy this stock and take advantage of near-term catalysts like EUA filings. The post Novavax Stock Is on the Way with Ramp up in EUA Filings appeared first on InvestorPlace.

Novavax Stock Is on the Way with Ramp up in EUA Filings

Moderna

For most of the past two years, all the focus has been on the coronavirus, but these biotechs have big plans to develop inoculations against other diseases, too.

3 Vaccine Stocks With Big Opportunities Outside of COVID-19

Coinbase

Zogenix

Wall Street projects aggregate sales growth of 509% to 3,324% for these stocks.

4 of the Fastest-Growing Stocks on the Planet Through 2024

Novavax looks cheap at just 6 times forward earnings. NVAX stock is likely worth at least 85% more at $314 once it receives vaccine approval.

Novavax Looks Like a Bargain with Its Low Forward Earnings Multiple

After securing its first EUA from the Republic of Indonesia, Novavax is poised to receive a string of use authorizations from a variety of centers around the globe.

Novavax Screams Buy

Hims & Hers Health

Invitae

Analyst price targets for three top growth stocks suggest big gains just up ahead.

3 Stocks That Could Soar 46% or More, According to Wall Street

NVAX stock boasts one of the strongest long-term cases in the biotech industry despite being criticized by the press. The post Ignore the Naysayers and Invest in Novavax Stock appeared first on InvestorPlace.

Ignore the Naysayers and Invest in Novavax Stock

Los Angeles, California--(Newsfile Corp. - November 8, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novavax is the subject of an article published by Politico on October...

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novavax, Inc. and Encourages Investors with Losses to Contact the Firm

News for Novavax Stock (NVAX)